Noticias relacionadas con terapia génica y celular.
Un mensaje del presidente de la SETGYC
Review written by Alessandro Aiuti, Giuliana Ferrari & Adrien Thrasher
New Horizons in the Management of ADA-SCID is a free educational resource for healthcare professionals managing patients with this rare disease.
CDTI invests together with Inveready Biotech III and EASO Ventures in VIVEbiotech, a biotechnology startup that develops and produces viral vectors to be applied in gene therapy
MeiraGTx is very excited to let you know they released positive data for their AAV-RPGR program to treat X-Linked retinitis pigmentosa!
To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines. The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.
San Sebastián, Spain, June 4, 2020 - VIVEbiotech, S.L., a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces a collaboration with Xyphos Biosciences for the development its CAR-T™ cell therapy for people with hematological cancer.
the gene therapy for the treatment of ADA-SCID was originally developed by Ospedale San Raffaele (OSR) and Fondazione Telethon (Telethon), through their joint San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) and was taken forward by GSK through a strategic collaboration formed in 2010
Declaración de apoyo a la Directiva Europea 2010/63/UE (“Directiva”) relativa a la protección de los animales utilizados para fines científicos
New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome
First stem-cell therapy recommended for approval in EU New treatment for rare condition caused by burns to the eye
Noticias